Rosenblit, Paul D.
Article History
First Online: 22 July 2019
Change Date: 6 November 2019
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake.
Compliance with Ethical Standards
:
: <b>12-month 1/1/18-12/31/18 disclosure</b>Paul D. Rosenblit received clinical trial research site funding from Amgen, AstraZeneca, Dexcom, GlaxoSmithKline, Ionis, Mylan, and Novo Nordisk. He received speaker faculty honoraria from Akcea, Amgen, Merck, and Novo Nordisk. He received advisory board honoraria from Akcea, Esperion, and Novo Nordisk.
: This article does not contain any studies with human or animal subjects performed by any of the authors.